Literature DB >> 24850498

[Prevention in the elderly: position paper on pneumococcal vaccinations. Results of an expert workshop on 15 November 2013 in Cologne, Germany].

G Fätkenheuer1, A Kwetkat, M W Pletz, J Schelling, R-J Schulz, M van der Linden, T Welte.   

Abstract

Infections due to pneumococci especially in the elderly are vastly underestimated, e.g., because non-invasive infections such as pneumonia may appear with only few symptoms. Sequential vaccination with the pneumococcal conjugate vaccine PCV13, followed by the 23-valent polysaccharide vaccine, is considered as the best preventive measure for individual protection, even though clinical study data demonstrating the efficacy of this sequence are not yet available. Increase of "awareness" by use of computer-based reminder functions may result in a significant improvement of vaccination compliance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24850498     DOI: 10.1007/s00391-014-0650-9

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  28 in total

1.  Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.

Authors:  Mark van der Linden; Susanne Weiß; Gerhard Falkenhorst; Annette Siedler; Matthias Imöhl; Rüdiger von Kries
Journal:  Vaccine       Date:  2012-07-04       Impact factor: 3.641

Review 2.  Pneumococcal vaccination in adults: does it really work?

Authors:  Georgia G Pitsiou; Ioannis P Kioumis
Journal:  Respir Med       Date:  2011-08-04       Impact factor: 3.415

3.  Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003.

Authors:  R R Reinert; S Haupts; M van der Linden; C Heeg; M Y Cil; A Al-Lahham; D S Fedson
Journal:  Clin Microbiol Infect       Date:  2005-12       Impact factor: 8.067

4.  Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years.

Authors:  Tino F Schwarz; Beate Schmoele-Thoma
Journal:  Vaccine       Date:  2012-11-02       Impact factor: 3.641

5.  Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines.

Authors:  R von Kries; A Siedler; H J Schmitt; R R Reinert
Journal:  Clin Infect Dis       Date:  2000-08-30       Impact factor: 9.079

6.  Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.

Authors:  Mathias W R Pletz; Lesley McGee; James Jorgensen; Bernard Beall; Richard R Facklam; Cynthia G Whitney; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial.

Authors:  Takaya Maruyama; Osamu Taguchi; Michael S Niederman; John Morser; Hiroyasu Kobayashi; Tetsu Kobayashi; Corina D'Alessandro-Gabazza; Sei Nakayama; Kimiaki Nishikubo; Takashi Noguchi; Yoshiyuki Takei; Esteban C Gabazza
Journal:  BMJ       Date:  2010-03-08

8.  Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.

Authors:  Lisa A Jackson; Alejandra Gurtman; Martin van Cleeff; Kathrin U Jansen; Deepthi Jayawardene; Carmel Devlin; Daniel A Scott; Emilio A Emini; William C Gruber; Beate Schmoele-Thoma
Journal:  Vaccine       Date:  2013-05-18       Impact factor: 3.641

9.  Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia.

Authors:  Jan Törling; Jonas Hedlund; Helle Bossen Konradsen; Ake Ortqvist
Journal:  Vaccine       Date:  2003-12-08       Impact factor: 3.641

10.  Pneumococcal conjugate vaccine for adults: a new paradigm.

Authors:  Peter R Paradiso
Journal:  Clin Infect Dis       Date:  2012-04-11       Impact factor: 9.079

View more
  4 in total

1.  [Pneumococcal vaccination for prevention of pneumonia].

Authors:  A Kwetkat; S Hagel; C Forstner; M W Pletz
Journal:  Z Gerontol Geriatr       Date:  2015-04-16       Impact factor: 1.281

2.  [Vaccinations in respiratory medicine].

Authors:  H M Lode; R Stahlmann
Journal:  HNO       Date:  2015-09       Impact factor: 1.284

3.  Pneumococcal vaccination rates in immunocompromised patients-A cohort study based on claims data from more than 200,000 patients in Germany.

Authors:  Niklas Schmedt; Julia Schiffner-Rohe; Ralf Sprenger; Jochen Walker; Christof von Eiff; Dennis Häckl
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

4.  Determinants of tetanus, pneumococcal and influenza vaccination in the elderly: a representative cross-sectional study on knowledge, attitude and practice (KAP).

Authors:  Carolina J Klett-Tammen; Gérard Krause; Linda Seefeld; Jördis J Ott
Journal:  BMC Public Health       Date:  2016-02-04       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.